These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25980599)

  • 1. Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.
    Monico LB; Mitchell SG; Gryczynski J; Schwartz RP; O'Grady KE; Olsen YK; Jaffe JH
    J Subst Abuse Treat; 2015 Oct; 57():57-62. PubMed ID: 25980599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
    Shulman M; Wai JM; Nunes EV
    CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
    Allen E; Samadian S; Altobelli G; Johnson J; Holmwood C
    Drug Alcohol Rev; 2023 May; 42(4):791-802. PubMed ID: 36788357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.
    Gryczynski J; Jaffe JH; Schwartz RP; Dušek KA; Gugsa N; Monroe CL; O'Grady KE; Olsen YK; Mitchell SG
    Am J Addict; 2013; 22(3):285-91. PubMed ID: 23617873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
    Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
    Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steps physicians report taking to reduce diversion of buprenorphine.
    Yang A; Arfken CL; Johanson CE
    Am J Addict; 2013; 22(3):184-7. PubMed ID: 23617857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of outcome after short-term stabilization with buprenorphine.
    Hillhouse M; Canamar CP; Ling W
    J Subst Abuse Treat; 2013 Mar; 44(3):336-42. PubMed ID: 23021099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.
    Gordon MS; Vocci FJ; Taxman F; Fishman M; Sharma B; Blue TR; O'Grady KE
    Contemp Clin Trials; 2019 Apr; 79():21-27. PubMed ID: 30797042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 20. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.